Epirium
Bruce Fahr has a long history of work experience in the field of chemistry. Bruce started their career in 2000 as a Staff Scientist at Sunesis Pharmaceuticals. In 2007, they joined Celgene as a Principal Scientist and Senior Scientist I. In 2016, they became the Principal at BF Consulting. From 2017 to 2021, they worked as a Research Scientist at PMV Pharmaceuticals, Inc. Bruce is currently the Director Of Chemistry at Epirium.
Bruce Fahr attained a PostDoc from Stanford University in 2000, after completing their Ph.D. in Synthetic organic chemistry from the University of California, Los Angeles in 1998.
Epirium
Epirium is a clinical-stage biopharmaceutical company that has developed unique insights related to the biology of mitochondrial biogenesis and tissue function, potentially resulting in novel therapeutic approaches to currently intractable neuromuscular diseases.